– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of…
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase…
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that…
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin…
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with…
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on…
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the…
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded…
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial…
Express-TekSM Production enables customers to have their products enter production in days instead of weeks, significantly shortening turnaround time New…